Cargando…

CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis

BACKGROUND: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (palbociclib and abemaciclib) and mammalian target of rapamycin (mTOR) inhibitors (everolimus) are effective agents for restoring endocrine sensitivity in patients with advanced breast cancer progression on prior aromatase inhibitors. We co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Hong-Wei, Huang, Li-Sheng, Xu, Qi-Ni, Wang, Hong-Biao, Li, Xu-Yuan, Lin, Jia-Zhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344177/ https://www.ncbi.nlm.nih.gov/pubmed/30608416 http://dx.doi.org/10.1097/MD.0000000000013909

Ejemplares similares

Current development of the second generation of mTOR inhibitors as anticancer agents
por: Zhou, Hong-Yu, et al.
Publicado: (2012)

Zhuanggu Zhitong Capsule alleviates postmenopausal osteoporosis in ovariectomized rats by regulating autophagy through AMPK/mTOR signaling pathway
por: Men, Zhitao, et al.
Publicado: (2022)

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
por: Ji, Danyang, et al.
Publicado: (2023)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
por: Rodriguez, María Jimena, et al.
Publicado: (2023)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade
por: Woess, Katharina, et al.
Publicado: (2022)

Blockade of the mTOR signaling pathway with rapamycin ameliorates aristolochic acid nephropathy
por: Wu, Minmin, et al.
Publicado: (2020)

CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation
por: Shuda, Masahiro, et al.
Publicado: (2015)

Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Regulates Neurite Outgrowth Through the Activation of Akt/mTOR and Erk/mTOR Signaling Pathways
por: Wen, Wen, et al.
Publicado: (2020)

Therapeutic mTOR blockade in systemic autoimmunity: Implications for antiviral immunity and extension of lifespan
por: Geier, Christian, et al.
Publicado: (2021)

Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt–mTOR and Cyclin–CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines
por: Rutz, Jochen, et al.
Publicado: (2022)

Hypo-Expression of Tuberin Promotes Adenomyosis via the mTOR1-Autophagy Axis
por: Gu, Ni-Hao, et al.
Publicado: (2021)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)

The roles of METTL3 on autophagy and proliferation of vascular smooth muscle cells are mediated by mTOR rather than by CDK1
por: Luo, Hanshen, et al.
Publicado: (2023)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

mTOR Signaling in Metabolism and Cancer
por: Huang, Shile
Publicado: (2020)

CircRNA-100338 Is Associated With mTOR Signaling Pathway and Poor Prognosis in Hepatocellular Carcinoma
por: Huang, Xiu-Yan, et al.
Publicado: (2019)

Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
por: Bai, Xin, et al.
Publicado: (2021)

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
por: Esfahani, Khashayar, et al.
Publicado: (2019)

mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation in vitro and in vivo
por: Chen, Sijia, et al.
Publicado: (2020)

MAPK6-AKT signaling promotes tumor growth and resistance to mTOR kinase blockade
por: Cai, Qinbo, et al.
Publicado: (2021)

Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity
por: Yang, Qichao, et al.
Publicado: (2022)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials
por: Xu, Hangcheng, et al.
Publicado: (2022)

Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin
por: Ou, Da-Liang, et al.
Publicado: (2014)

A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling
por: Wu, Alexander T. H., et al.
Publicado: (2021)

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
por: Wu, Xianbo, et al.
Publicado: (2022)

Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
por: Benavides-Serrato, Angelica, et al.
Publicado: (2017)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis
por: Pollizzi, Kristen, et al.
Publicado: (2009)

mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis
por: Gui, Yao-Song, et al.
Publicado: (2015)

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
por: Abu-Khalaf, Maysa M., et al.
Publicado: (2023)

Predicted mechanisms of resistance to mTOR inhibitors
por: Kurmasheva, R T, et al.
Publicado: (2006)

mTOR regulates GPVI-mediated platelet activation
por: Wang, Longsheng, et al.
Publicado: (2021)

Neuroligin 3 Regulates Dendritic Outgrowth by Modulating Akt/mTOR Signaling
por: Xu, Jing, et al.
Publicado: (2019)

Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
por: Pelicano, Hélène, et al.
Publicado: (2014)

Trehalose, sucrose and raffinose are novel activators of autophagy in human keratinocytes through an mTOR-independent pathway
por: Chen, Xu, et al.
Publicado: (2016)

Liver-adipose tissue crosstalk in alcohol-associated liver disease: The role of mTOR
por: Rodriguez, Yssa, et al.
Publicado: (2022)

Hedyotis diffusa Willd. Suppresses Hepatocellular Carcinoma via Downregulating AKT/mTOR Pathways
por: Huang, Lingli, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ivife3cir6er0o2pgatmor53ga